eptifibatidă - search results

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

integrilin solution for infusion

glaxo operations uk ltd. - eptifibatide - solution for infusion - 0,75mg/ml

integrilin solution for injection

glaxo operations uk ltd. - eptifibatide - solution for injection - 2mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

integrilin

merck sharp & dohme (new zealand) limited - eptifibatide 0.75 mg/ml - solution for injection - 0.75 mg/ml - active: eptifibatide 0.75 mg/ml excipient: citric acid monohydrate water for injection - integrilin is indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction (chest pain with stsegment depression >0.5 mm or definitive t-wave inversion >1 mm or transient st-segment elevation >0.5 mm of less than 30 minutes or persistent st-segment elevation >0.5 mm not requiring reperfusion therapy or thrombolytic agents, or chest pain in patients without persistent st-segment elevation with ck-mb greater than the upper limit of normal). integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. patients with unstable angina (ua) or non-q-wave myocardial infarction (nqmi) who are most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first three to four days after onset of acute angina symptoms, including for instance those that are likely to undergo an early pci. integrilin is intended for use with aspirin, heparin and clopidigrel.

New Zealand - English - Medsafe (Medicines Safety Authority)

integrilin

merck sharp & dohme (new zealand) limited - eptifibatide 2 mg/ml - solution for injection - 2 mg/ml - active: eptifibatide 2 mg/ml excipient: citric acid monohydrate water for injection - integrilin is indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction (chest pain with stsegment depression >0.5 mm or definitive t-wave inversion >1 mm or transient st-segment elevation >0.5 mm of less than 30 minutes or persistent st-segment elevation >0.5 mm not requiring reperfusion therapy or thrombolytic agents, or chest pain in patients without persistent st-segment elevation with ck-mb greater than the upper limit of normal). integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. patients with unstable angina (ua) or non-q-wave myocardial infarction (nqmi) who are most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first three to four days after onset of acute angina symptoms, including for instance those that are likely to undergo an early pci. integrilin is intended for use with aspirin, heparin and clopidigrel.